Sort
10,766 grants matching “checkpoint inhibitor”
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$596,039John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2018 · CA
The Genetics of Ocular Melanoma
$596,016Anne Mary Bowcock · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Bottlebrush polymer prodrugs for targeted delivery of combination therapies and in vivo imaging of pharmacological response
$595,926Jeremiah Allen Johnson · Massachusetts Institute Of Technology · R01 · FY2025 · CA
Engineering immunotherapeutic probiotics to mitigate irAE
$595,682Tal Danino · Columbia Univ New York Morningside · U01 · FY2021 · CA
Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening
$595,679Joseph C Wu · Stanford University · R01 · FY2023 · HL
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
$595,576Jun Wang · New York University School Of Medicine · R01 · FY2023 · CA
An urinary drug disposing approach for treatment of bladder Cancer
$595,483Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Mouse models of Kras-mutant colorectal cancer
$595,434Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
$595,374Dmitriy Zamarin · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Molecular Pathways Regulating Tissue-resident Memory T cells in the Gut
$595,247Michael Lawrence Dougan · Massachusetts General Hospital · R01 · FY2023 · AI
Molecular Pathways Regulating Tissue-resident Memory T cells in the Gut
$595,247Michael Lawrence Dougan · Massachusetts General Hospital · R01 · FY2025 · AI
Molecular Pathways Regulating Tissue-resident Memory T cells in the Gut
$595,247Michael Lawrence Dougan · Massachusetts General Hospital · R01 · FY2024 · AI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$594,846Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2022 · AI
Genetically-engineered Bacteria Overcome Therapy Resistance
$594,699Ralph R Weichselbaum · University Of Chicago · R01 · FY2025 · CA
Reorienting the Glioblastoma Microenvironment to Respond to Immunotherapy
$594,636Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2019 · NS
Rational targeting of Cdc42 to benefit immunotherapy
$594,402Yi Zheng · Cincinnati Childrens Hosp Med Ctr · R01 · FY2024 · CA
Rational targeting of Cdc42 to benefit immunotherapy
$594,402Yi Zheng · Cincinnati Childrens Hosp Med Ctr · R01 · FY2025 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
$594,336Zihai Li · Ohio State University · R01 · FY2022 · CA
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma
$594,335Michael Daniel Green · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Cancer immunotherapy
$594,136Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
RIG-I Activating Nanoparticles for Immunopotentiation
$594,047John Tanner Wilson · Vanderbilt University · R01 · FY2023 · EB
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
$594,010Mitch A Phelps · Ohio State University · R01 · FY2024 · CA
Multiscale analysis of metabolic inflammation as a driver of breast cancer
$593,459Gerald V Denis · Boston University Medical Campus · U01 · FY2020 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$593,411Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2022 · CA
Ascorbic acid as a pharmacologic agent in disease treatment
$593,140Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK